924274-94-2Relevant academic research and scientific papers
HETEROARYL RHEB INHIBITORS AND USES THEREOF
-
Paragraph 00719, (2018/11/10)
The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.
MK2 INHIBITORS AND USES THEREOF
-
Paragraph 001217, (2014/10/03)
The present invention provides compounds, compositions thereof, and methods of using the same.
COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS
-
Page/Page column 64, (2014/11/13)
The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds and salts of general Formula VIII Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a patient, including Pseudomonas aeruginosa infections, are also provided by the disclosure.
Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
-
Page/Page column 38, (2008/06/13)
The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
